Skip to main content

Table 3 Changes in biochemical parameters among the study groups

From: Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial

Parameters

Linagliptin group

(n = 10)

Voglibose group

(n = 9)

Control group

(n = 7)

P-Value Linagliptin V/S Control

P-Value Voglibose V/S Control

P-Value Voglibose V/S Linagliptin

∆HbA1c (%)

−0.2(− 0.6 to 0.3)

−0.8(− 0.9 to − 0.1)

0.1(− 0.1 to 0.3)

0.422

0.038a

0.723

Mixed Meal Tolerance Test

 ∆AUC C-pep (nmol/L)

−100.5 (− 174.8 to 75.6)

− 80.3 (− 217.6 to 15.0)

−24.9 (− 153.2184.6)

0.669

0.470

0.780

 ∆M0 × 10− 8 (1/min)

1.5(0.2 to 2.7)

3.5(− 1.4 to 3.9)

3.7(0.6 to 6.7)

0.497

0.918

0.475

 ∆M1 ×10−8 (1/min)

−2.1(−3.7 to 0.2)

−3.3(−6.4 to 2.1)

−3.8(− 6.1 to 0.6)

0.842

1.000

0.536

Hyperinsulinemic-Euglycemic Clamp Study

 ∆Glucose disposal rate (mg/Kg min)

0.5(−0.2 to 0.7)

0.2(0.1 to 0.5)

0.1(−0.4 to 0.4)

0.536

0.470

0.842

 ∆Insulin sensitivity (mg/(Kgmin)/μU/mL)

0.6(−1.5 to 1.3)

0.2(−0.9 to 0.9)

0.2(−0.8 to 0.7)

0.601

0.905

0.837

  1. All values are expressed as median and interquartile range (1st IQR to 3rd IQR). −Decrease from baseline. aSignificant difference within the group
  2. AUC Area under curve, M0 Basal β-cell function, M1 postprandial β-cell function